We rank companies based on fund manager, research analyst and news sentiment
ANIK stock icon

Anika Therapeutics Inc
ANIK

$25
2.38%
 

About: Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Employees: 357

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]

80% more call options, than puts

Call options by funds: $61.2K | Put options by funds: $34K

24% more capital invested

Capital invested by funds: $242M [Q3] → $300M (+$58M) [Q4]

1.8% more ownership

Funds ownership: 88.7% [Q3] → 90.5% (+1.8%) [Q4]

3% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 40

0% more funds holding

Funds holding: 116 [Q3] → 116 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 21

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$22
12%
downside
Avg. target
$29
16%
upside
High target
$37
48%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Barrington Research
Michael Petusky
48%upside
$37
Outperform
Maintained
14 Mar 2024
Stephens & Co.
George Sellers
12%downside
$22
Equal-Weight
Reiterated
14 Mar 2024
Barrington Research
Michael Petusky
16%upside
$29
Outperform
Maintained
3 Jan 2024
Barrington Research
Michael Petusky
12%upside
$28
Outperform
Maintained
3 Nov 2023

Financial journalist opinion